Genprex announced research showing low TROP2 protein levels are associated with resistance to its gene therapy drug Reqorsa in non-small cell lung cancer (NSCLC). This finding, supported by preclinical models and patient biopsy analysis, suggests TROP2 could serve as a biomarker to select patients likely to respond to treatment. The research will be presented at the 2026 EORTC-NCI-AACR Symposium, highlighting potential for more personalized lung cancer therapies. Further studies are needed to confirm TROP2's predictive value and explore ways to enhance Reqorsa's effectiveness by modulating TROP2 signaling.
Genprex's new research on TROP2 as a biomarker in lung cancer provides context for health sector trends. For readers following health stocks, here is Pluang's market snapshot as of Nov 04, 2026 18:01 WIB: out of 150 priced US health-sector stocks, 95 rose and 41 fell. Notable movers include Novo Nordisk A/S (NVO) at USD 41.73 with a 3.83% increase and 90% buy order activity, Abeona Therapeutics Inc (ABEO) at USD 4.41 up 3.76% with 100% buy orders, and TransMedics Group Inc (TMDX) at USD 69.85 rising 3.73% with full buy interest.
KE Holdings Inc., a major online and offline housing platform in China, will announce its unaudited financial results for the third quarter of 2026 on November 16 before the U.S. market opens. The company will host an earnings conference call at 7:00...
JD.com announced it will publish its unaudited financial results for the third quarter of 2026 on November 17, before the U.S. market opens. The company's management will hold a conference call the same day to discuss the results, providing investors...
Dimensional Fund Advisors Ltd. filed a Form 8.3 disclosure revealing it holds a 1.27% stake in Prologis Inc as of November 3, 2026. This disclosure is part of regulatory requirements under the Takeover Code for investors holding 1% or more in relevan...
Dimensional Fund Advisors Ltd. has disclosed an interest in 1,516,595 ordinary shares of DCC Energy plc, representing 1.78% of the company's shares as of November 3, 2026. The disclosure follows regulatory requirements under the Irish Takeover Panel ...
Wayfair reported Q3 2026 net revenue of $3.4 billion, up 9.7% year-over-year, driven by an 11.4% increase in U.S. revenue. Active customers grew 4.7% to 22.2 million, with orders up 12.2%, signaling strong market share gains. The company posted a net...
